• Je něco špatně v tomto záznamu ?

High CD4-to-CD8 ratio identifies an at-risk population susceptible to lethal COVID-19

M. De Zuani, P. Lazničková, V. Tomašková, M. Dvončová, G. Forte, GB. Stokin, V. Šrámek, M. Helán, J. Frič

. 2022 ; 95 (3) : e13125. [pub] 20211213

Jazyk angličtina Země Velká Británie

Typ dokumentu časopisecké články, pozorovací studie

Perzistentní odkaz   https://www.medvik.cz/link/bmc22010915

Grantová podpora
CZ.02.1.01/0.0/0.0/15_003/0000492 European Social Fund and European Regional Development Fund-Project MAGNET
CZ.02.1.01/0.0/0.0/16_019/0000868 ENOCH
NV18-06-00529 Ministry of Health of the Czech Republic
NU21J-05-00056 Ministry of Health of the Czech Republic
00023736 DRO (Institute of Hematology and Blood Transfusion - UHKT)
European Regional Development Fund - Project
CZ.02.2.69/0.0/0.0/19_074/0016274 FNUSA-ICRC

E-zdroje Online Plný text

NLK Free Medical Journals od 1997 do Před 1 rokem
Medline Complete (EBSCOhost) od 1972-01-01 do Před 1 rokem
Wiley Free Content od 1997 do Před 1 rokem

Around half of people with severe COVID-19 requiring intensive care unit (ICU) treatment will survive, but it is unclear how the immune response to SARS-CoV-2 differs between ICU patients that recover and those that do not. We conducted whole-blood immunophenotyping of COVID-19 patients upon admission to ICU and during their treatment and uncovered marked differences in their circulating immune cell subsets. At admission, patients who later succumbed to COVID-19 had significantly lower frequencies of all memory CD8+ T cell subsets, resulting in increased CD4-to-CD8 T cell and neutrophil-to-CD8 T cell ratios. ROC and Kaplan-Meier analyses demonstrated that both CD4-to-CD8 and neutrophil-to-CD8 ratios at admission were strong predictors of in-ICU mortality. Therefore, we propose the use of the CD4-to-CD8 T cell ratio as a marker for the early identification of those individuals likely to require enhanced monitoring and/or pro-active intervention in ICU.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc22010915
003      
CZ-PrNML
005      
20220506130553.0
007      
ta
008      
220425s2022 xxk f 000 0|eng||
009      
AR
024    7_
$a 10.1111/sji.13125 $2 doi
035    __
$a (PubMed)34861051
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxk
100    1_
$a De Zuani, Marco $u International Clinical Research Center, St. Anne's University Hospital Brno, Brno, Czech Republic $1 https://orcid.org/0000000212302714
245    10
$a High CD4-to-CD8 ratio identifies an at-risk population susceptible to lethal COVID-19 / $c M. De Zuani, P. Lazničková, V. Tomašková, M. Dvončová, G. Forte, GB. Stokin, V. Šrámek, M. Helán, J. Frič
520    9_
$a Around half of people with severe COVID-19 requiring intensive care unit (ICU) treatment will survive, but it is unclear how the immune response to SARS-CoV-2 differs between ICU patients that recover and those that do not. We conducted whole-blood immunophenotyping of COVID-19 patients upon admission to ICU and during their treatment and uncovered marked differences in their circulating immune cell subsets. At admission, patients who later succumbed to COVID-19 had significantly lower frequencies of all memory CD8+ T cell subsets, resulting in increased CD4-to-CD8 T cell and neutrophil-to-CD8 T cell ratios. ROC and Kaplan-Meier analyses demonstrated that both CD4-to-CD8 and neutrophil-to-CD8 ratios at admission were strong predictors of in-ICU mortality. Therefore, we propose the use of the CD4-to-CD8 T cell ratio as a marker for the early identification of those individuals likely to require enhanced monitoring and/or pro-active intervention in ICU.
650    _2
$a senioři $7 D000368
650    _2
$a poměr CD4 a CD8 lymfocytů $x metody $7 D016516
650    _2
$a CD4-pozitivní T-lymfocyty $x imunologie $7 D015496
650    _2
$a CD8-pozitivní T-lymfocyty $x imunologie $7 D018414
650    _2
$a COVID-19 $x imunologie $7 D000086382
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé $7 D006801
650    _2
$a imunofenotypizace $x metody $7 D016130
650    _2
$a jednotky intenzivní péče $7 D007362
650    _2
$a počet lymfocytů $x metody $7 D018655
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a prospektivní studie $7 D011446
650    _2
$a SARS-CoV-2 $x imunologie $7 D000086402
655    _2
$a časopisecké články $7 D016428
655    _2
$a pozorovací studie $7 D064888
700    1_
$a Lazničková, Petra $u International Clinical Research Center, St. Anne's University Hospital Brno, Brno, Czech Republic $u Department of Biology, Faculty of Medicine, Masaryk University, Brno, Czech Republic $1 https://orcid.org/0000000316330517
700    1_
$a Tomašková, Veronika $u Department of Anaesthesiology and Intensive Care, Faculty of Medicine, Masaryk University, Brno, Czech Republic $1 https://orcid.org/0000000265652531
700    1_
$a Dvončová, Martina $u Department of Anaesthesiology and Intensive Care, Faculty of Medicine, Masaryk University, Brno, Czech Republic
700    1_
$a Forte, Giancarlo $u International Clinical Research Center, St. Anne's University Hospital Brno, Brno, Czech Republic $1 https://orcid.org/0000000213411023
700    1_
$a Stokin, Gorazd Bernard $u International Clinical Research Center, St. Anne's University Hospital Brno, Brno, Czech Republic $u Celica BIOMEDICAL, Ljubljana, Slovenia $1 https://orcid.org/0000000184308755
700    1_
$a Šrámek, Vladimir $u Department of Anaesthesiology and Intensive Care, Faculty of Medicine, Masaryk University, Brno, Czech Republic
700    1_
$a Helán, Martin $u International Clinical Research Center, St. Anne's University Hospital Brno, Brno, Czech Republic $u Department of Anaesthesiology and Intensive Care, Faculty of Medicine, Masaryk University, Brno, Czech Republic $1 https://orcid.org/0000000290214947
700    1_
$a Frič, Jan $u International Clinical Research Center, St. Anne's University Hospital Brno, Brno, Czech Republic $u Institute of Hematology and Blood Transfusion, Prague, Czech Republic $1 https://orcid.org/000000016642797X
773    0_
$w MED00010600 $t Scandinavian journal of immunology $x 1365-3083 $g Roč. 95, č. 3 (2022), s. e13125
856    41
$u https://pubmed.ncbi.nlm.nih.gov/34861051 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20220425 $b ABA008
991    __
$a 20220506130545 $b ABA008
999    __
$a ok $b bmc $g 1788840 $s 1162113
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2022 $b 95 $c 3 $d e13125 $e 20211213 $i 1365-3083 $m Scandinavian journal of immunology $n Scand J Immunol $x MED00010600
GRA    __
$a CZ.02.1.01/0.0/0.0/15_003/0000492 $p European Social Fund and European Regional Development Fund-Project MAGNET
GRA    __
$a CZ.02.1.01/0.0/0.0/16_019/0000868 $p ENOCH
GRA    __
$a NV18-06-00529 $p Ministry of Health of the Czech Republic
GRA    __
$a NU21J-05-00056 $p Ministry of Health of the Czech Republic
GRA    __
$a 00023736 $p DRO (Institute of Hematology and Blood Transfusion - UHKT)
GRA    __
$p European Regional Development Fund - Project
GRA    __
$a CZ.02.2.69/0.0/0.0/19_074/0016274 $p FNUSA-ICRC
LZP    __
$a Pubmed-20220425

Najít záznam

Citační ukazatele

Nahrávání dat ...

Možnosti archivace

Nahrávání dat ...